Anti-inflammatory effects of ruxolitinib on chronic neutrophilic leukemia harboring CSF3R-T618I mutation with bilateral renal abscesses. (2022)

• Record Type: Journal Article
• Authors: Sahara, Naohi; Yokoyama, Kazuaki; Matsunaga, Takashi; Kitahara, Shinsuke; Fujii, Tomoki; Kobayashi, Seiichiro; Yusa, Nozomi; Shimizu, Eigo; Imoto, Seiya; Tojo, Arinobu; Ohno, Nobuhiro
• Is Part Of: Leukemia research reports. Volume 18(2022)
• Publication Date: 2022
• Subjects: Chronic neutrophilic leukemia -- CSF3R-T618I mutation -- Bilateral renal abscesses -- Ruxolitinib; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2022.100348
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm (MPN) characterized by sustained mature neutrophilic leukocytosis. Recently, presence of colony-stimulating factor 3 receptor ( CSF3R ) mutations has been added to the diagnostic criteria for CNL. Anti-inflammatory effects of the JAK1/2 inhibitor ruxolitinib relieve constitutional symptoms associated with MPN, such as fatigue, night sweats, and fever. We present a case of CNL harboring CSF3R- T618I mutation exacerbated by concomitant bilateral renal abscesses, which was refractory to antibiotics, at the time of initial diagnosis. In this case, ruxolitinib rapidly improved not only CNL but the infection, due to its anti-inflammatory potency.